Lisa Ray Highlights Chemotherapy-Induced Early Menopause and Fertility Challenges

ବ୍ୟବସାୟ

ସାଗରମାଳା ଯୋଜନାରେ ଓଡ଼ିଶାକୁ ବଡ଼ ପ୍ରୋତ୍ସାହନ: ୫୬ ହଜାର କୋଟିର...

July 22, 2026

ପାରାଦୀପରେ ହେବ ୫୦୦ କୋଟି ଟଙ୍କାର କ୍ରିଟିକାଲ୍ ମିନେରାଲ୍ ପ୍ରୋସେସିଂ...

July 22, 2026

ଆଦାନୀ ଏନର୍ଜିର ବଡ଼ ସଫଳତା: ପ୍ରଥମ ତ୍ରୟମାସିକରେ ୧୨୪% ବଢ଼ିଲା...

July 21, 2026

ଲୋୟର ସୁକତେଲ ପ୍ରକଳ୍ପକୁ ନେଇ ପୁଣି ବଢ଼ିଲା ଉତ୍ତେଜନା, ଗ୍ରାମ...

July 21, 2026

ଶିକ୍ଷା

ମାଓବାଦୀ ପ୍ରଭାବିତ ଗାଁରୁ IIT ପର୍ଯ୍ୟନ୍ତ: ମୟୂରଭଞ୍ଜର ଆଦିବାସୀ ଛାତ୍ର...

July 22, 2026

APAAR ID ପାଇଁ ଅଭିଭାବକଙ୍କ ସମ୍ମତି ସମ୍ପୂର୍ଣ୍ଣ ସ୍ୱଇଚ୍ଛାଧୀନ ହେବ:...

July 21, 2026

SCERT ପାଠ୍ୟପୁସ୍ତକ ତ୍ରୁଟି ମାମଲା: ଆଗୁଆ ଜାମିନ ପାଇଁ ହାଇକୋର୍ଟର...

July 21, 2026

ଓଡ଼ିଶାରେ ଏକକ-ଶିକ୍ଷକ ବିଦ୍ୟାଳୟ ସଂଖ୍ୟାରେ ୩୪% ବୃଦ୍ଧି, UDISE+ ରିପୋର୍ଟରେ...

July 21, 2026

Lisa Ray Highlights Chemotherapy-Induced Early Menopause and Fertility Challenges

Actor Lisa Ray revealed that chemotherapy pushed her into early menopause at 37, shedding light on fertility and hormonal issues many young cancer survivors face. Experts stress early counselling and fertility preservation strategies are crucial before treatment begins.

Published by Somesh | February 18, 2026

Actor Lisa Ray’s revelation that chemotherapy induced early menopause at the age of 37 has sparked a vital conversation on an often-overlooked aspect of cancer treatment. Diagnosed with multiple myeloma in 2009, Ray spoke about the emotional and physical challenges of losing fertility and experiencing menopause unexpectedly, highlighting a gap in survivorship care.

Medical experts explain that chemotherapy, while targeting rapidly dividing cancer cells, can also damage ovarian cells, reduce egg reserves, and in some cases trigger temporary or permanent menopause. Women over 35–40, those undergoing longer treatment durations, or receiving certain drugs like alkylating agents are at higher risk.

Fortunately, protective strategies exist if discussed early. Fertility preservation options include egg or embryo freezing, ovarian tissue freezing, and the use of GnRH analogues to temporarily suppress ovarian function during chemotherapy. In cases where pelvic radiation is planned, ovarian transposition may also be considered. While no method guarantees prevention, early planning significantly improves outcomes.

Chemotherapy-induced menopause, often called “chemopause,” remains under-discussed. During diagnosis, the primary focus is survival, and reproductive or hormonal concerns may feel secondary. Social stigma around discussing reproductive health further contributes to the lack of awareness.

Hormone replacement therapy (HRT) can alleviate menopausal symptoms and protect bone and cardiovascular health but must be individualized. In hormone-sensitive cancers, HRT is generally avoided, while survivors without hormone-driven cancers may consider it under medical guidance.

Ray’s candid disclosure underscores that surviving cancer involves more than treatment success. Informed discussions about fertility, symptom management, and long-term hormonal health are essential for improving the quality of life for women undergoing chemotherapy.